Design Therapeutics Appoints Justin Gover as Director

An update from Design Therapeutics ( (DSGN) ) is now available.

On September 9, 2025, Arsani William, M.D., resigned from the board of directors of Design Therapeutics, Inc., with no disagreements related to the company’s operations. On the same day, Justin Gover was appointed as a Class III director and chair of the Compensation Committee, with his term ending at the 2027 annual meeting of stockholders. Mr. Gover will receive an annual cash retainer and stock options as part of the company’s compensation policy.

The most recent analyst rating on (DSGN) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Design Therapeutics stock, see the DSGN Stock Forecast page.

Spark’s Take on DSGN Stock

According to Spark, TipRanks’ AI Analyst, DSGN is a Neutral.

Design Therapeutics has significant financial challenges due to its lack of revenue and profitability, which heavily weighs on its score. Despite a strong balance sheet and positive technical indicators suggesting short-term momentum, the negative valuation metrics and absence of earnings diminish its overall appeal. The stock is risky and reliant on future revenue growth for improvement.

To see Spark’s full report on DSGN stock, click here.

More about Design Therapeutics

Average Trading Volume: 123,408

Technical Sentiment Signal: Buy

Current Market Cap: $331.4M

See more data about DSGN stock on TipRanks’ Stock Analysis page.